Literature DB >> 16785458

Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus.

Carlo Bellini1, Francesco Campone, Giovanni Serra.   

Abstract

Patent ductus arteriosus is one of the most common congenital abnormalities found in premature infants. Ibuprofen, a nonsteroidal drug that is commonly used as an antipyretic, analgesic and anti-inflammatory agent, is also used to induce closure of symptomatic patent ductus arteriosus in preterm infants. Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension. Only 3 cases of pulmonary hypertension following early administration of an ibuprofen solution buffered with tromethamine have previously been reported. However, this severe side effect has never been observed in multicentre, randomized, double-blind controlled trials, nor in recent reviews or meta-analyses of L-lysine ibuprofen use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785458      PMCID: PMC1475921          DOI: 10.1503/cmaj.051446

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  7 in total

1.  Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial.

Authors:  V Gournay; J C Roze; A Kuster; P Daoud; G Cambonie; J M Hascoet; C Chamboux; T Blanc; C Fichtner; C Savagner; J B Gouyon; V Flurin; G Thiriez
Journal:  Lancet       Date:  2004 Nov 27-Dec 3       Impact factor: 79.321

Review 2.  A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.

Authors:  Ronald L Thomas; Graham C Parker; Bart Van Overmeire; Jacob V Aranda
Journal:  Eur J Pediatr       Date:  2004-12-10       Impact factor: 3.183

3.  Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.

Authors:  V Gournay; C Savagner; G Thiriez; A Kuster; J-C Rozé
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

4.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

5.  Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Bart Van Overmeire; Karel Allegaert; Alexandra Casaer; Christian Debauche; Wim Decaluwé; Ann Jespers; Joost Weyler; Inge Harrewijn; Jean-Paul Langhendries
Journal:  Lancet       Date:  2004 Nov 27-Dec 3       Impact factor: 79.321

Review 6.  Treatment of patent ductus arteriosus.

Authors:  Jonathan Wyllie
Journal:  Semin Neonatol       Date:  2003-12

Review 7.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  S S Shah; A Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2003
  7 in total
  14 in total

1.  Effects of combined hyperoxia and cyclooxygenase inhibition in neonatal rat lungs.

Authors:  Katherine M Kuniyoshi; Romy S Brock; Bisrat H Gebrekristos; Matthew Abad-Santos; Dinh Hoang; Houchang D Modanlou; Brigham C Willis; Kay D Beharry
Journal:  Am J Transl Res       Date:  2010-06-08       Impact factor: 4.060

2.  Re-examining our approach to the approval and use of new drugs.

Authors:  Shoo K Lee
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

3.  Indomethacin therapy for patent ductus arteriosus in premature infants.

Authors:  K-S Lee
Journal:  Pediatr Cardiol       Date:  2008-09       Impact factor: 1.655

4.  Patent ductus arteriosus: an overview.

Authors:  James E Dice; Jatinder Bhatia
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

5.  Clinical experience with intravenous Ibuprofen lysine in the pharmacologic closure of patent ductus arteriosus.

Authors:  Evelyn R Hermes-Desantis; Jacob V Aranda
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

6.  Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors:  Karen E Corff; Kris C Sekar
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 7.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

Review 8.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

9.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

Review 10.  Management of hypoxemic respiratory failure and pulmonary hypertension in preterm infants.

Authors:  N Ambalavanan; J L Aschner
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.